Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer

Anand Jillella, Gw Britt, Ms Litaker, Am Kallab, K. Harkness, Gd Garner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Our purpose was to determine the risk of ototoxicity in breast cancer patients receiving a myeloablative regimen consisting of cyclophosphamide 6000 mg/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2 (CTCb) followed by stem cell transplantation. Fourteen consecutive patients with breast cancer were treated with high dose chemotherapy consisting of the CTCb regimen followed by stem cell transplantation. A pre-transplant complete hearing study was obtained which consisted of hearing case history, audiometry and tympanometry. In addition, DPOAE (Distortion Product Otoaccoustic Emissions) was done to evaluate measurable changes in the cochlear (outer hair cell) functioning. Pre-transplant, all patients had no clinical evidence of hearing impairment and hearing studies were normal. Eleven patients had hearing studies and a telephone interview post-transplant. One patient was lost to follow-up and two patients died. One of the 11 patients tested had an abnormal post-transplant hearing study but none of them had clinically detectable hearing impairment. In our prospective study of breast cancer patients treated with the CTCb regimen, we did not observe clinically detectable hearing impairment in any of the patients tested.

Original languageEnglish (US)
Pages (from-to)287-292
Number of pages6
JournalMedical Oncology
Volume17
Issue number4
DOIs
StatePublished - Jan 1 2000

Fingerprint

Thiotepa
Carboplatin
Stem Cell Transplantation
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Hearing
Hearing Loss
Transplants
Outer Auditory Hair Cells
Acoustic Impedance Tests
Audiometry
Lost to Follow-Up
Prospective Studies
Interviews

Keywords

  • Autologous stem cell transplantation
  • Breast cancel
  • Carboplatin
  • Otoaccoustic emissions
  • Ototoxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer. / Jillella, Anand; Britt, Gw; Litaker, Ms; Kallab, Am; Harkness, K.; Garner, Gd.

In: Medical Oncology, Vol. 17, No. 4, 01.01.2000, p. 287-292.

Research output: Contribution to journalArticle

@article{aea657fbc219498ab3258394a76bfc40,
title = "Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer",
abstract = "Our purpose was to determine the risk of ototoxicity in breast cancer patients receiving a myeloablative regimen consisting of cyclophosphamide 6000 mg/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2 (CTCb) followed by stem cell transplantation. Fourteen consecutive patients with breast cancer were treated with high dose chemotherapy consisting of the CTCb regimen followed by stem cell transplantation. A pre-transplant complete hearing study was obtained which consisted of hearing case history, audiometry and tympanometry. In addition, DPOAE (Distortion Product Otoaccoustic Emissions) was done to evaluate measurable changes in the cochlear (outer hair cell) functioning. Pre-transplant, all patients had no clinical evidence of hearing impairment and hearing studies were normal. Eleven patients had hearing studies and a telephone interview post-transplant. One patient was lost to follow-up and two patients died. One of the 11 patients tested had an abnormal post-transplant hearing study but none of them had clinically detectable hearing impairment. In our prospective study of breast cancer patients treated with the CTCb regimen, we did not observe clinically detectable hearing impairment in any of the patients tested.",
keywords = "Autologous stem cell transplantation, Breast cancel, Carboplatin, Otoaccoustic emissions, Ototoxicity",
author = "Anand Jillella and Gw Britt and Ms Litaker and Am Kallab and K. Harkness and Gd Garner",
year = "2000",
month = "1",
day = "1",
doi = "10.1007/BF02782193",
language = "English (US)",
volume = "17",
pages = "287--292",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer

AU - Jillella, Anand

AU - Britt, Gw

AU - Litaker, Ms

AU - Kallab, Am

AU - Harkness, K.

AU - Garner, Gd

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Our purpose was to determine the risk of ototoxicity in breast cancer patients receiving a myeloablative regimen consisting of cyclophosphamide 6000 mg/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2 (CTCb) followed by stem cell transplantation. Fourteen consecutive patients with breast cancer were treated with high dose chemotherapy consisting of the CTCb regimen followed by stem cell transplantation. A pre-transplant complete hearing study was obtained which consisted of hearing case history, audiometry and tympanometry. In addition, DPOAE (Distortion Product Otoaccoustic Emissions) was done to evaluate measurable changes in the cochlear (outer hair cell) functioning. Pre-transplant, all patients had no clinical evidence of hearing impairment and hearing studies were normal. Eleven patients had hearing studies and a telephone interview post-transplant. One patient was lost to follow-up and two patients died. One of the 11 patients tested had an abnormal post-transplant hearing study but none of them had clinically detectable hearing impairment. In our prospective study of breast cancer patients treated with the CTCb regimen, we did not observe clinically detectable hearing impairment in any of the patients tested.

AB - Our purpose was to determine the risk of ototoxicity in breast cancer patients receiving a myeloablative regimen consisting of cyclophosphamide 6000 mg/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2 (CTCb) followed by stem cell transplantation. Fourteen consecutive patients with breast cancer were treated with high dose chemotherapy consisting of the CTCb regimen followed by stem cell transplantation. A pre-transplant complete hearing study was obtained which consisted of hearing case history, audiometry and tympanometry. In addition, DPOAE (Distortion Product Otoaccoustic Emissions) was done to evaluate measurable changes in the cochlear (outer hair cell) functioning. Pre-transplant, all patients had no clinical evidence of hearing impairment and hearing studies were normal. Eleven patients had hearing studies and a telephone interview post-transplant. One patient was lost to follow-up and two patients died. One of the 11 patients tested had an abnormal post-transplant hearing study but none of them had clinically detectable hearing impairment. In our prospective study of breast cancer patients treated with the CTCb regimen, we did not observe clinically detectable hearing impairment in any of the patients tested.

KW - Autologous stem cell transplantation

KW - Breast cancel

KW - Carboplatin

KW - Otoaccoustic emissions

KW - Ototoxicity

UR - http://www.scopus.com/inward/record.url?scp=0033763905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033763905&partnerID=8YFLogxK

U2 - 10.1007/BF02782193

DO - 10.1007/BF02782193

M3 - Article

VL - 17

SP - 287

EP - 292

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 4

ER -